曲妥珠单抗联合化疗在接受改良根治术并行术后化疗初治乳腺癌患者中的应用

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application of Trastuzumab combined with chemotherapy in patients with breast cancer who underwent modified radical mastectomy and postoperative chemotherapy.Methods A total of 81 patients with newly treated breast cancer who underwent modified radical mastectomy and postoperative chemotherapy in our hospital from January 2015 to January 2017 were selected as research subjects.They were divided into a control group(n=40) and a study group (n=41) according to random number table method.The control group was treated with Docetaxel + Carboplatin method, and the study group was treated with combination of Trastuzumab and chemotherapy.The tumor load and immunity function of the two groups were compared.Results The levels of serum tumor markers including carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA153, and CA125 in the study group were lower than those in the control group, and the differences were statistically significant (P＜0.05).The levels of serum tumor active molecules like vascular endothelial growth factor (VEGF), nectin-4, thymidine kinase-1 (TK-1), platelet factor 4(PF-4), and tumor specific growth factor (TSGF) in the study group were lower than those in the control group, the differences were statistically significant (P＜0.05).The ratio of serum CD3+, CD4+ lymphocyte, and CD4+/CD8+ in the study group were higher than those in the control group, and the ratio of CD8+ lymphocyte was lower than that in the control group, the differences were statistically significant (P ＜0.05).Conclusion The use of Trastuzumab combined with chemotherapy after improved radical mastectomy for breast cancer can reduce the tumor of breast cancer patients and improve their immune response, which has clinical application value.

Key words： Breast cancer Trastuzumab Tumor load Immunity function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GONG Yu-ai
	SHU Cheng-rong
	HAN Qi

Cite this article:

GONG Yu-ai,SHU Cheng-rong,HAN Qi. Application of Trastuzumab combined with chemotherapy in patients with breast cancer who underwent modified radical mastectomy and postoperative chemotherapy[J]. 中国当代医药, 2020, 27(22): 83-86.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I22/83

[1]	赵庆丽，马骥.阿司匹林联合曲妥珠单抗对HER-2 阳性乳腺癌细胞增殖和凋亡的影响[J].临床肿瘤学杂志，2017，22（12）：1091-1095.
[2]	张建兴.多种影像学方法在中国乳腺癌筛查中的应用[J].实用医学杂志，2017，33（9）：1365-1368.
[3]	Hart CD，Migliaccio I，Malorni L，et al.Challenges in the management of advanced，ER-positive，HER2-negative breast cancer[J].Nat Rev Clin Oncol，2015，12（9）：541-552.
[4]	彭宗玉，杜国威，温红.探讨乳癌根治术后放化疗对乳腺癌中晚期患者机体免疫力的影响[J].中国实用医药，2016，11（21）：214-215.
[5]	徐玲，叶京明，朱赛楠，等.HER-2 阳性早期乳腺癌TCH方案新辅助治疗疗效分析[J].中华医学杂志，2018，98（12）：907-911.
[6]	曾慧，唐雪苗.曲妥珠单抗在乳腺癌患者治疗中的心脏毒性[J].实用医学杂志，2017，33（12）：2056-2058.
[7]	中国抗癌协会乳腺癌专业委员会.Her-2 阳性乳腺癌临床诊疗专家共识[J].中国癌症杂志，2012，22（4）：314-318.
[8]	Bartsch R，Berghoff A，Pluschnig U，et al.Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases[J].Br J Cancer，2012，106（1）：25-31.
[9]	Gradishar W，Salerno KE.NCCN Guidelines Update:Breast Cancer[J].J Natl Compr Canc Netw，2016，14（5S）：641-644.
[10]	黄玉琴.注射用曲妥珠单抗对人表皮生长因子受体2 阳性晚期乳腺癌化疗患者血清肿瘤标志物及免疫功能的影响[J].中国综合临床，2017，33（8）：748-752.
[11]	徐虹，冀学宁.曲妥珠单抗在Her-2 阳性乳腺癌治疗中的心脏毒性[J].中国实用医药，2019，14（13）：187-190.
[12]	郑林静.曲妥珠单抗对乳腺癌术后新辅助化疗患者血清TIMP-1/2、MMP-2/9 的影响[J].实用癌症杂志，2019，34（9）：1424-1427.
[13]	于强，彭世军.中药联合化疗治疗晚期乳腺癌疗效及对血清CEA、CA125、CA153 和CA19-9 水平的影响[J].现代中西医结合杂志，2019，28（17）：1878-1881.
[16]	闻国权，吴淑仪，黎冠宏.赫赛汀联合阿霉素脂质体治疗HER-2 阳性乳腺癌的肿瘤负荷及毒副反应评估[J].海南医学院学报，2016，22（23）：2869-2872.
[17]	尹子毅，张铁，曲更宝，等.TP 方案联合曲妥珠单抗治疗人表皮生长因子受体2 阳性乳腺癌的疗效评价[J].癌症进展，2019，17（12）：1391-1394.
[14]	Wang YJ，Huang XY，Mo M，et al.Serum tumor marker levels might have little significance in evaluating neoadjuvant treatment response in locally advanced breast cancer[J].Asian Pac J Cancer Prev，2015，16（11）：4603-8.
[15]	Fejzipagenumber_ebook=92,pagenumber_book=86 H，Mujagipagenumber_ebook=92,pagenumber_book=86 S，Azabagipagenumber_ebook=92,pagenumber_book=86S，et al.Tumor marker CA 15-3 in breast cancer patients[J].Acta Med Acad，2015，44（1）：39-46.
[18]	严婕，何建怀，胡雄强.曲妥珠单抗、吉西他滨、紫杉醇联合疗法对转移性乳腺癌患者血清肿瘤标志物和免疫功能的影响[J].实用癌症杂志，2019，34（6）：919-922.